Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy

Abstract

AbstractMinimal/measurable residual disease (MRD) is the most important independent prognostic factor for patients with B‐lymphoblastic leukemia (B‐LL). MRD post therapy has been incorporated into risk stratification and clinical management, resulting in substantially improved outcomes in pediatric and adult patients. Currently, MRD in B‐ALL is most commonly assessed by multiparametric flow cytometry and molecular (polymerase chain reaction or high‐throughput sequencing based) methods. The detection of MRD by flow cytometry in B‐ALL often begins with B cell antigen‐based gating strategies. Over the past several years, targeted immunotherapy directed against B cell markers has been introduced in patients with relapsed or refractory B‐ALL and has demonstrated encouraging results. However, targeted therapies have significant impact on the immunophenotype of leukemic blasts, in particular, downregulation or loss of targeted antigens on blasts and normal B cell precursors, posing challenges for MRD detection using standard gating strategies. Novel flow cytometric approaches, using alternative strategies for population identification, sometimes including alternative gating reagents, have been developed and implemented to monitor MRD in the setting of post targeted therapy.